Business Standard

Cipla receives USFDA final approval for Valganciclovir Tablets 450mg

Image

Capital Market
Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Valganciclovir Tablets 450mg from the United States Food and Drug Administration (US FDA).

Cipla's Valganciclovir Tablets 450mg is AB-rated generic therapeutic equivalent version of Roche's Valcyte. It is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for use in the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) and prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Nov 12 2018 | 8:47 AM IST

Explore News